Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 359-367 , September 2008

Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study

  • Pia Baumann

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden
    • Corresponding Author InformationCorresponding author. Pia Baumann, Department of Oncology, Karolinska University Hospital Solna and Karolinska Institutet, Radiumhemmet, S-171 76 Stockholm, Sweden.
    • ,
  • Jan Nyman

      Affiliations

    • Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden
    • ,
  • Morten Hoyer

      Affiliations

    • Divisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark
    • ,
  • Giovanna Gagliardi

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden
    • ,
  • Ingmar Lax

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden
    • ,
  • Berit Wennberg

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden
    • ,
  • Ninni Drugge

      Affiliations

    • Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden
    • ,
  • Lars Ekberg

      Affiliations

    • Divisions of Oncology and Hospital Physics, Malmö University Hospital, Sweden
    • ,
  • Signe Friesland

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden
    • ,
  • Karl-Axel Johansson

      Affiliations

    • Department of Oncology and Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden
    • ,
  • Jo-Åsmund Lund

      Affiliations

    • Department of Oncology, Trondheim University Hospital, Norway
    • ,
  • Elisabeth Morhed

      Affiliations

    • Department of Oncology and Radiotherapy, Akademiska University Hospital, Uppsala, Sweden
    • ,
  • Kristina Nilsson

      Affiliations

    • Department of Oncology and Radiotherapy, Akademiska University Hospital, Uppsala, Sweden
    • ,
  • Nina Levin

      Affiliations

    • Department of Oncology, Trondheim University Hospital, Norway
    • ,
  • Merete Paludan

      Affiliations

    • Divisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark
    • ,
  • Christer Sederholm

      Affiliations

    • Department of Oncology, Linköping University Hospital, Sweden
    • ,
  • Anders Traberg

      Affiliations

    • Divisions of Oncology and Medical Physics, Aarhus University Hospital, Denmark
    • ,
  • Lena Wittgren

      Affiliations

    • Divisions of Oncology and Hospital Physics, Malmö University Hospital, Sweden
    • ,
  • Rolf Lewensohn

      Affiliations

    • Divisions of Oncology and Hospital Physics, Radiumhemment, Karolinska University Hospital, Sweden

Received 8 February 2008 ,Revised 27 June 2008 ,Accepted 16 July 2008.

References 

  1. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–1431
  2. Onishi H. Stereotactic radiotherapy for body tumors (mainly lung). Nippon Hoshasen Gijutsu Gakkai Zasshi. 2006;62:661–669
  3. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–S100
  4. Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45:796–801
  5. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007;2:S101–S112
  6. Scorsetti M, Navarria P, Facoetti A, Lattuada P, Urso G, Mirandola A, et al. Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. Anticancer Res. 2007;27:3615–3619
  7. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103
  8. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–1015
  9. http://www.roc.se/lungca.asp: Svenska lungcancer registret.
  10. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res. 2005;6:98
  11. http://ctep.cancer.gov.
  12. www.rtog.org/members/toxicity/late.html.
  13. Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–683
  14. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  15. Lax I, Panettieri V, Wennberg B, Amor Duch M, Naslund I, Baumann P, et al. Dose distributions in SBRT of lung tumors: comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions. Acta Oncol. 2006;45:978–988
  16. Panettieri V, Wennberg B, Gagliardi G, Duch MA, Ginjaume M, Lax I. SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol. 2007;52:4265–4281
  17. Djarv E, Nyman J, Baumann P, Ekberg L, Hoyer M, Lax I, et al. Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. Acta Oncol. 2006;45:973–977
  18. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol. 2007;2:S118–S124
  19. Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, et al. Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology. 2004;230:101–108
  20. Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys. 2006;66:483–491
  21. Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007;85:435–442
  22. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, et al. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007;2:21
  23. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83–87
  24. Timmerman R, Bastasch M, Saha D, Abdulrahman R, Hittson W, Story M. Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol. 2007;40:352–365
  25. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  26. Kadono K, Homma T, Kamahara K, Nakayama M, Satoh H, Sekizawa K, et al. Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients. Chest. 2002;122:1925–1932
  27. Ohashi T, Takeda A, Shigematsu N, Kunieda E, Ishizaka A, Fukada J, et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys. 2005;62:1003–1008
  28. Travis EL, Liao ZX, Tucker SL. Spatial heterogeneity of the volume effect for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys. 1997;38:1045–1054
  29. Tucker SL, Liao ZX, Travis EL. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys. 1997;38:1055–1066
  30. Paludan M, Traberg Hansen A, Petersen J, Grau C, Hoyer M. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency?. Acta Oncol. 2006;45:818–822
  31. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  32. Henderson M, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;

PII: S0167-8140(08)00384-8

doi: 10.1016/j.radonc.2008.07.019

Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 359-367 , September 2008

Article Tools

* Image Usage & Resolution